www.marijuanamoment.net
Open in
urlscan Pro
2606:4700:3035::ac43:d621
Public Scan
URL:
https://www.marijuanamoment.net/why-some-activists-fear-marijuana-rescheduling-responding-to-former-fda-officials-dismissal-of-o...
Submission: On January 10 via manual from US — Scanned from US
Submission: On January 10 via manual from US — Scanned from US
Form analysis 3 forms found in the DOM
GET https://www.marijuanamoment.net/
<form method="get" id="searchform" action="https://www.marijuanamoment.net/">
<input type="text" name="s" id="s" value="Search" onfocus="if (this.value == "Search") { this.value = ""; }" onblur="if (this.value == "") { this.value = "Search"; }">
<input type="hidden" id="searchsubmit" value="Search">
</form>POST
<form id="mc4wp-form-2" class="mc4wp-form mc4wp-form-869" method="post" data-id="869" data-name="Marijuana News In Your Inbox">
<div class="mc4wp-form-fields">
<p>
<label>Email address: </label>
<input type="email" name="EMAIL" placeholder="Your email address" required="">
</p>
<p>
<input type="submit" value="Sign up">
</p>
</div><label style="display: none !important;">Leave this field empty if you're human: <input type="text" name="_mc4wp_honeypot" value="" tabindex="-1" autocomplete="off"></label><input type="hidden" name="_mc4wp_timestamp"
value="1704898215"><input type="hidden" name="_mc4wp_form_id" value="869"><input type="hidden" name="_mc4wp_form_element_id" value="mc4wp-form-2">
<div class="mc4wp-response"></div>
</form>POST
<form id="mc4wp-form-3" class="mc4wp-form mc4wp-form-869" method="post" data-id="869" data-name="Marijuana News In Your Inbox">
<div class="mc4wp-form-fields">
<p>
<label>Email address: </label>
<input type="email" name="EMAIL" placeholder="Your email address" required="">
</p>
<p>
<input type="submit" value="Sign up">
</p>
</div><label style="display: none !important;">Leave this field empty if you're human: <input type="text" name="_mc4wp_honeypot" value="" tabindex="-1" autocomplete="off"></label><input type="hidden" name="_mc4wp_timestamp"
value="1704898215"><input type="hidden" name="_mc4wp_form_id" value="869"><input type="hidden" name="_mc4wp_form_element_id" value="mc4wp-form-3">
<div class="mc4wp-response"></div>
</form>Text Content
* Politics
* Science & Health
* Culture
* Business
* Video
* Newsletter
* Subscribe
* Remove Ads
* Bill Tracking
* About
* Login Instructions
* All 2024 Cannabis Bills
* Bill Hearing Calendar
* About Marijuana Moment
* Support Marijuana Moment
* Subscribe To Newsletter
Connect with us
*
*
*
MARIJUANA MOMENT
WHY SOME ACTIVISTS FEAR MARIJUANA RESCHEDULING: RESPONDING TO FORMER FDA
OFFICIAL’S DISMISSAL OF OUR CONCERNS (OP-ED)
* Politics
* Minnesota Police And Regulators Will Meet To Address ‘Loophole’ Allowing
Sale Of Raw ‘Hemp’ Flower That May Be Marijuana
* After Several Failed Efforts, Washington Lawmakers Introduce New Bill To
Legalize Home Marijuana Cultivation
* Why Some Activists Fear Marijuana Rescheduling: Responding To Former FDA
Official’s Dismissal Of Our Concerns (Op-Ed)
* South Carolina Senator Pushes For Medical Marijuana Vote Next Month
* Rhode Island Bill Would Temporarily Legalize Psilocybin Use, Home
Cultivation And Sharing
* Science & Health
* Medical Marijuana Is ‘Similarly Effective’ As Opioids For Treating Pain
But With Fewer Adverse Events, Study Finds
* Colleges In States That Legalize Marijuana See Spike In Applications From
Higher Achieving Students, Study Finds
* Study Finds Most Cancer Survivors Who Used Marijuana Reported ‘Great
Degree Of Symptomatic Improvement’
* Using Marijuana Before Working Out Can Enhance Enjoyment And ‘Runner’s
High,’ But Also Cause More Exertion, Study Finds
* Most Military Service Members, Veterans And Their Families Support
Allowing VA Doctors To Recommend Marijuana And Psychedelics
* Culture
* UFC Formally Removes Marijuana From Banned Substances List For
Professional Fighters
* State Officials Promote Marijuana Gifting, Infused Baking And Safety Tips
For The Holiday Season
* States That Legalize Marijuana See Enhanced College Basketball
Recruitment, Study Finds
* Carnival Cruise Lines Denies That Anti-Marijuana Enforcement Measures Are
Meant To Boost Alcohol Sales On Ships
* SXSW Announces 2024 Lineup, Leaning Into Psychedelics While Nixing
Cannabis Track
* Business
* New Mexico Sets New Monthly Marijuana Sales Record, With Purchases Topping
A Half-Billion Dollars In First Full Year Of Recreational Market
* Maine Sets Another Marijuana Sales Record In 2023
* Mississippi Regulators Place Hold On ‘Large Number Of’ Medical Marijuana
After Receiving Anonymous Call
* New York Posts Dozens Of Sample Marijuana Job Descriptions To Aid
Businesses And Workers
* Rhode Island Marijuana Retailers Hit $100 Million Milestone During First
Year Of Adult-Use Sales
* Video
* West Virginia Senate President Says Marijuana Could Be Legalized To Help
Curb Fentanyl Epidemic, ‘Sooner Than Later’
* Wisconsin Republicans Unveil Plan To Legalize Non-Smokable Medical
Marijuana With State-Run Dispensaries
* DeSantis Says He Would ‘Respect The Decisions That States Make’ On
Marijuana Legalization, Despite Personal Opposition
* Wisconsin Governor Says He’ll ‘Absolutely’ Sign Limited GOP Medical
Marijuana Bill, Unless It Contains ‘Poison Pills’
* Kentucky Governor Pushes Lawmakers To Approve More Medical Marijuana
Qualifying Conditions While Unveiling First Program Rules
* Newsletter
* Legal cannabis can combat fentanyl, WV Senate leader says (Newsletter:
January 10, 2024)
* Hawaii AG’s legal cannabis report (Newsletter: January 9, 2024)
* CO gov bashes DeSantis’s cannabis stance (Newsletter: January 8, 2024)
* KY gov’s cannabis expansion push (Newsletter: January 5, 2024)
* DEA cannabis rescheduling update (Newsletter: January 4, 2024)
* Subscribe
* Remove Ads
* Bill Tracking
* About
* Login Instructions
* All 2024 Cannabis Bills
* Bill Hearing Calendar
* About Marijuana Moment
* Support Marijuana Moment
* Subscribe To Newsletter
POLITICS
WHY SOME ACTIVISTS FEAR MARIJUANA RESCHEDULING: RESPONDING TO FORMER FDA
OFFICIAL’S DISMISSAL OF OUR CONCERNS (OP-ED)
Published
2 hours ago
on
January 10, 2024
By
Marijuana Moment
“This is the Judgment Day that we all predicted while sharing a conspiratorial
joint in the dark days of prohibition. It’s surreal to see our fears manifesting
in real time.”
By Deb Tharp, NuggMD
Politico recently published an extensive Q&A with Howard Sklamberg, a former top
Food and Drug Administration (FDA) official who currently works at the law firm
Arnold and Porter. Many advocates for legalization and restorative justice have
concerns about the rescheduling of cannabis to a Schedule III substance—fears
that Sklamberg believes are “alarmist and misguided.”
A New Poll Finds That Floridians Want Legal Marijuana
A new poll from the University of North Florida finds broad support for a state
constitutional amendment legalizing marijuana–but that proposal is currently
under review by the state supreme court. Veuer’s Matt Hoffman has the details.
More Videos
0 seconds of 46 secondsVolume 0%
Press shift question mark to access a list of keyboard shortcuts
Keyboard ShortcutsEnabledDisabled
Play/PauseSPACE
Increase Volume↑
Decrease Volume↓
Seek Forward→
Seek Backward←
Captions On/Offc
Fullscreen/Exit Fullscreenf
Mute/Unmutem
Decrease Caption Size-
Increase Caption Size+ or =
Seek %0-9
Next Up
States That Legalized Marijuana See Massive Reduction in Tobacco Use
00:43
facebook twitter Email pinterest
Linkhttps://cdn.jwplayer.com/previews/LtKtK73c
Copied
Live
00:00
00:46
00:46
As a longtime advocate, I have to say that I don’t share that view. Honestly, I
can’t believe Sklamberg said some of the things that he said—and I think the
fears that we have are well-informed, reasoned and practical, if for no other
reason than the worrying lack of transparency coming from regulatory agencies
since rescheduling was recommended last year. We advocates are not always right,
but our track record on drug policy is better than that of the policymakers and
regulators who campaigned for, created and continued the so-called war on drugs.
Regulators, elected officials and their surrogates could benefit from hearing
and taking seriously the other side: the concerns that advocates have about
cannabis rescheduling. I’ve done my best to capture some of them below.
Sklamberg:
“I find it to be a very strange and not understandable myth that enforcement
would increase as cannabis is rescheduled from Schedule I to Schedule III.”
“If you’re going to launch an enforcement initiative against cannabis, why would
you start off with saying, ‘Oh, by the way, it’s less of a risk than we
thought’? You would use your power under Schedule I and go after it.”
No-knock raids aren’t our only concern under Schedule III, although it’s still a
top concern, since rescheduling doesn’t remove criminal penalties. Activists are
just as concerned about the impending regulatory quagmire. Cannabis businesses
are already failing by a substantial margin due to excessive state regulations.
Big Pharma drug patent lawsuits and increased FDA involvement will drive out the
few surviving businesses—businesses built by the fearless activists who paved
the way for legalization. It’s inevitable, and whether that result is
intentional or not is irrelevant. The end result will be the same.
> “I don’t think that drug companies would go through years of development and
> patenting without attempting to completely corner their share of the market.”
A move to Schedule III directs FDA to regulate cannabis like a pharmaceutical
drug. Why else would they keep it in the Controlled Substances Act? That’s like
saying, “I have this axe here, but I’m only going to use it to peel your apples,
not chop down your tree.”
State-legal cannabis operators are under dire threat in the absence of
congressional action to protect the current marketplace. The
Rohrabacher–Blumenauer amendment prohibits the Justice Department from spending
funds to interfere with the implementation of state medical cannabis laws, but
it has to be renewed every year. Legislation that makes it permanent, and
applicable to state-legal recreational markets as well, is needed
immediately—and it’s worth mentioning that the first session of the 118th
Congress was the least productive in modern U.S. history. There is no reason to
believe legislative action is forthcoming along with rescheduling.
Sklamberg:
“They [state-legal cannabis programs] are subject to FDA regulations now. The
thing is, FDA chooses not to enforce them. Why would FDA all of a sudden want to
enforce those when it hadn’t in the past under Schedule I?”
An anti-enforcement agenda isn’t FDA’s “choice.” The agency doesn’t have the
clarity or the public support to interfere with the state-legal markets.
Consider FDA’s stance on psychoactive hemp products. It recently asked Congress
to grant clarity for regulating these products. To me, that’s a pretty big tell.
Sklamberg:
“FDA does not have resources for cannabis.”
This is a bit like saying the raccoon you saw yesterday in your garden hasn’t
come back around and ruined it yet because he’s down the block, going through
some garbage. It may be true, but it’s not very reassuring. Are activists happy
that FDA purportedly doesn’t have resources for cannabis? Yes, sure. But we
don’t think this represents any guarantee or guidance on the agency’s posture if
cannabis were rescheduled.
The fact is that FDA will be given broad power and resources to regulate and
enforce against unapproved commercial cannabinoids. If this wasn’t the current
plan, then they would be descheduling instead of rescheduling, and
FDA-controlled, Big Pharma-driven cannabis is the wrong approach. Why should
anyone trust this vital herb to the same actors who ruthlessly created the
opioid crisis and then campaigned against cannabis legalization to prevent
competition from a safer alternative? (This isn’t an unwarranted medical claim.
It is absolutely indisputable that cannabis use is safer than opiate use.)
Furthermore, if cannabis becomes a Schedule III drug under FDA’s purview instead
of an agricultural crop, as it should be, then the agency will be required to
enforce the privileges it grants. There are currently dozens of cannabis-based
pharmaceuticals that have applied for orphan drug status. Simply type “canna” in
the “product name” search box for FDA’s Orphan Drug Designations and Approvals
database to see for yourself.
State-legal markets won’t be allowed to simply continue as they are with dozens
of newly patented products clamoring for their market share. I don’t think that
drug companies would go through years of development and patenting without
attempting to completely corner their share of the market. That’s not how the
pharmaceutical industry works. It’s not really how any industry works.
Sklamberg:
“If there were a new administration, and they wanted to take enforcement, it’d
be more likely to come from the DEA. But they would face a similar problem: If
you’re going to take merely symbolic enforcement action, you’re going to open
yourself up to the criticism of favoritism and it being arbitrary, which is
something agencies cannot do.”
We’re all adults here, so I’ll just be real: Every administration and state
government since Nixon has been engaging in symbolic enforcement against
cannabis. About half of adults have tried the substance, and this hasn’t served
as a deterrent to this impossible war against it. Why should we think that they
would embrace their limitations now after nearly half a century of futile
aggression against the American people?
Both DEA and FDA enforcement are financially incentivized. State agencies are
financially incentivized for enforcement too. This is why we still see hundreds
of thousands of marijuana arrests per year despite our attempts to get
regulators and law enforcement to see reason.
The arrests drive profits. Asset forfeiture, punitive fines, even prison terms
result in financial benefits for enforcers, and marijuana users make for an easy
target. Sklamberg’s question is what is their incentive to enforce. My question
is, what is their incentive to stop?
Again, even if their symbolic and arbitrary enforcement isn’t intentionally
harmful to society as a whole, the end result is the same. The data on race and
cannabis enforcement alone speaks for itself. In many states, the racial divide
in enforcement has increased over the past decade, even as total arrests
decrease. Fear of criticism hasn’t stopped these misguided agencies yet, and I
don’t see Schedule III changing that.
Sklamberg:
“If you’re talking about conducting clinical trials and filing new drug
applications for specific cannabis drugs, that is a lengthy and expensive
process. Practically speaking, there would still be this medical cannabis
industry. The approved drug would try to convince agencies to take action
against some of the medical cannabis companies.”
This reads to me like an acknowledgment of our worst fears. It admits to two
things: a potential FDA enforcement agenda and the validation of activists’
concerns that drug companies would just sue cannabis operators into oblivion
under Schedule III.
There is not a single reason to get a patent if there is no intention to
monopolize the value of the intellectual property it protects. Drug companies
are not known for just doing the consumer a solid. And they are already pursuing
cannabis patents.
Consider Epidiolex, which was granted orphan drug designation and immediately
rolled out of the gate with a $30,000-a-year price tag. All for a CBD compound
that might not even work as well as the concentrates activists were already
making in the state-legal and safety-tested market—concentrates they are
providing for a minuscule fraction of that cost. And the lawsuits over GW’s
overpriced pill have only just started flying.
We don’t have to speculate as to what will happen with approved THC drugs under
Schedule III. We can see it unfolding before our eyes with CBD.
Patent-related litigation from the pharmaceutical industry would be absolutely
devastating for cannabis operators who can already barely afford overwhelming
legal and regulatory costs. The Section 280E savings under Schedule III won’t
help them at all if they are forced to spend all of those tax savings on
litigation and regulatory defense.
Politico:
“But would moving marijuana to Schedule III make research easier?
Sklamberg:
“Depends on who you ask. There’s a bit of a debate on that. It can make it
somewhat easier, but the fact is clinical trials are still expensive, even if
you’re dealing with unscheduled [substances].
“For it to make business sense, you’d have to have a company willing to invest,
get the resources to do it. Spend the time doing this. And thinking, ‘Once we
get this approved, we’re going to be able to have a monopoly enforced.’ I don’t
see that as likely.”
Advocates see this as highly likely since we’re already witnessing it, and
assuming Schedule III happens, we’ll be able to see who’s right and who isn’t in
a handful of years.
Under Schedule III, we’ll see a floodgate of cannabis-related patent activity,
and the existing industry will drown in the impending tsunami of litigation.
Furthermore, activists aren’t willing to accept Sklamberg’s reassurances that
DEA may lose interest in criminal enforcement in trade for just letting this
scenario play out in the name of progress.
This is the Judgment Day that we all predicted while sharing a conspiratorial
joint in the dark days of prohibition. It’s surreal to see our fears manifesting
in real time.
THE OUTLOOK UNDER SCHEDULE III
Basic transparency from FDA would go a long way towards alleviating many of
these concerns that activists have, and I fully acknowledge that that is no
longer within Sklamberg’s job description. I always enjoy his interviews and
appreciate that he sees this issue through an entirely different lens. But
cannabis advocates have been subjected to these empty reassurances before. I
heard a similar tone and was called an alarmist during the campaign for
Proposition 64, which legalized cannabis in California. And where are we now?
The very people who built California’s industry have been choked out en masse by
a badly written law. So perhaps I’m jaded.
All of that said, here is my basic outlook for cannabis under Schedule III,
absent decisive action from Congress to protect state-legal markets:
* Massive amounts of patent litigation, which will eventually bankrupt the
surviving operators
* An organized weaponization of the justice system by Big Pharma as it clamors
for market share in a $100 billion industry
* Widespread confusion about which cannabis-related products and services are
legal and which aren’t at the consumer level
* FDA enforcement campaigns against operators based on a variety of theories
* Continued criminal enforcement and more lives ruined (there were over a
quarter million cannabis arrests last year, 92 percent of them for possession
alone)
* An even greater explosion in black market activity
* A gigantic blank space on the congressional docket where cannabis legislation
should be
Cannabis advocates are here, ready to have a thoughtful dialogue with regulators
about why descheduling cannabis and regulating it under USDA or existing,
already safe and tested state markets is the only reasonable option. New
cannabis regulations should balance the individual liberties of people with the
public health and safety mandate of regulatory bodies. We just can’t have that
conversation with ourselves.
Deb Tharp is head of legal and policy research at NuggMD, the largest telehealth
company for cannabis.
> Congressman Tells DEA To Reschedule Marijuana ‘As Swiftly As Possible’
Photo courtesy of Philip Steffan.
Marijuana Moment is made possible with support from readers. If you rely on our
cannabis advocacy journalism to stay informed, please consider a monthly Patreon
pledge.
Related Topics:featured
Up Next
After Several Failed Efforts, Washington Lawmakers Introduce New Bill To
Legalize Home Marijuana Cultivation
Don't Miss
South Carolina Senator Pushes For Medical Marijuana Vote Next Month
Marijuana Moment
YOU MAY LIKE
Minnesota Police And Regulators Will Meet To Address ‘Loophole’ Allowing Sale Of
Raw ‘Hemp’ Flower That May Be Marijuana
After Several Failed Efforts, Washington Lawmakers Introduce New Bill To
Legalize Home Marijuana Cultivation
Legal cannabis can combat fentanyl, WV Senate leader says (Newsletter: January
10, 2024)
South Carolina Senator Pushes For Medical Marijuana Vote Next Month
Rhode Island Bill Would Temporarily Legalize Psilocybin Use, Home Cultivation
And Sharing
Minnesota Marijuana Regulators Want Input On Packaging, Tracking And
Verification Rules
Advertisement
MARIJUANA NEWS IN YOUR INBOX
Email address:
Leave this field empty if you're human:
SUPPORT MARIJUANA MOMENT
*
*
*
* About Marijuana Moment
* Subscribe
* Sponsorship and Advertising
* Privacy Policy
All the cannabis news you need, all in one place. Copyright © 2017-2024
Marijuana Moment LLC ® and Tom Angell
Information from your device can be used to personalize your ad experience.
Do not sell or share my personal information.
A Raptive Partner Site
✕
Do not sell or share my personal information.
You have chosen to opt-out of the sale or sharing of your information from this
site and any of its affiliates. To opt back in please click the "Customize my ad
experience" link.
This site collects information through the use of cookies and other tracking
tools. Cookies and these tools do not contain any information that personally
identifies a user, but personal information that would be stored about you may
be linked to the information stored in and obtained from them. This information
would be used and shared for Analytics, Ad Serving, Interest Based Advertising,
among other purposes.
For more information please visit this site's Privacy Policy.
CANCEL
CONTINUE
MARIJUANA NEWS IN YOUR INBOX
Email address:
Leave this field empty if you're human:
×